Skip to main content
. 2007 Jul 2;110(9):3480–3488. doi: 10.1182/blood-2007-05-087940

Figure 7.

Figure 7

FTY impairs but does not abrogate GVL. A separate cohort of mice as described in Figure 6 were evaluated for survival (n = 8 per group). Both FTY-treated and control mice receiving splenocytes survived longer than mice not receiving splenocytes, indicative of a GVL effect (P ≤ .001). However, FTY-treated mice died before controls due to a greater tumor relapse, indicating that FTY impaired GVL effect under these experimental conditions (P = .01).